Injectable hydrogels
The present disclosure generally relates to injectable compositions. More particularly, the present disclosure relates to injectable, thermogelling hydrogels and associated methods. In one embodiment, the present disclosure provides for a composition comprising a poly(N-isopropylacrylamide)-based macromer and a polyamidoamine-based macromer.
1. A composition comprising a poly(N-isopropylacrylamide)-based macromer and a diamine-based macromer, wherein the poly(N-isopropylacrylamide)-based macromer has a polymer backbone comprising glycidyl methacrylate (GMA) and N-isopropylacrylamide (NiPAAm), and wherein the poly(N-isopropylacrylamide)-based macromer is cross-linked by the diamine-based macromer via the GMA of the poly(N-isopropylacrylamide)-based macromer and an amine functional group of the diamine-based macromer.
2. The composition of claim 1 wherein the poly(N-isopropylacrylamide)-based macromer is selected from the group consisting of p(NiPAAm-co-GMA), p(NiPAAm-co-GMA-co-DBA-co-AA), and p(NiPAAm-co-GMA-co-AAm).
3. The composition of claim 1 wherein the diamine-based macromer is a polyamidoamine macromer.
4. The composition of claim 3 wherein the polyamidoamine macromer comprises bisacrylamide.
5. The composition of claim 1 wherein the diamine-based macromer increases hydrophilicity of the composition.
6. The composition of claim 1 wherein the composition is liquid.
7. The composition of claim 1 further comprising mesenchymal stem cells.
8. The composition of claim 1 further comprising growth factors.
9. The composition of claim 1 further comprising mesenchymal stem cells and growth factors.
10. A method comprising:
combining a poly(N-isopropylacrylamide)-based macromer with a diamine-based macromer to form a composition, wherein the poly(N-isopropylacrylamide)-based macromer has a polymer backbone comprising glycidyl methacrylate (GMA) and N-isopropylacrylamide (NiPAAm); and
injecting the composition into a defect in a mammal immediately following combining the poly(N-isopropylacrylamide)-based macromer with a diamine-based macromer.
11. The method of claim 10 wherein the defect is a craniofacial defect.
12. The method of claim 10 wherein the poly(N-isopropylacrylamide) macromer is selected from the group consisting of p(NiPAAm-co-GMA), p(NiPAAm-co-GMA-co-DBA-co-AA), and p(NiPAAm-co-GMA-co-AAm).
13. The method of claim 10 wherein the wherein the diamine-based macromer is a polyamidoamine macromer.
14. The method of claim 13 wherein the polyamidoamine macromer comprises bisacrylamide.
15. The method of claim 10 wherein the composition does not impede tissue formation within the defect.
16. The method of claim 10 wherein the diamine-based macromer increases hydrophilicity of the composition and mitigates syneresis.